Evidence map›Paper›PMID 42368158›Full record

ArticleACS omega2026

Pharmacological Characterization of SLL-022CCP, a Selective κ‑Opioid Receptor Agonist with Potent Antinociceptive Effects and Low Central Side Effects.

Jiang-Wen Gui, Jia-Wen Luo, Deng-Gao Zhang, Zhi-Wen Wang, Chao Zhang, Meng Sun, Jia-Qi Tan, Si-Yuan Tang, Shao-Liang Duan, Yu-Liang Lin and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jiang-Wen GuiSchool of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China.
Jia-Wen LuoSchool of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China.
Deng-Gao ZhangDepartment of Medicinal Chemistry, School of Pharmaceutical Sciences, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China.
Zhi-Wen WangShandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China.
Chao ZhangShandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China.
Meng SunShandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China.
Jia-Qi TanShandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China.
Si-Yuan TangDepartment of Medicinal Chemistry, School of Pharmaceutical Sciences, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China.
Shao-Liang DuanDepartment of Medicinal Chemistry, School of Pharmaceutical Sciences, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China.
Yu-Liang LinDepartment of Medicinal Chemistry, School of Pharmaceutical Sciences, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China.
Min LiuShandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China.
Li-Jin FengShandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China.
Li-Ming ShaoDepartment of Medicinal Chemistry, School of Pharmaceutical Sciences, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China.ORCID https://orcid.org/0000-0003-0694-7011
Jing-Gen LiuShandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China.
Pan-Wen LiuShandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China.
Wei LiDepartment of Medicinal Chemistry, School of Pharmaceutical Sciences, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China.ORCID https://orcid.org/0000-0002-8449-3839
Yu-Jun WangShandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China.ORCID https://orcid.org/0000-0002-1206-5325

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The κ-opioid receptor (KOR) is recognized as a promising therapeutic target for the development of nonaddictive analgesics. However, the clinical utility of typical KOR agonists is limited by central adverse effects. SLL-022CCP is a novel KOR-selective ligand derived from a northebaine-based 4,5-epoxymorphinan scaffold, and we have previously demonstrated its high binding affinity for KOR. In this study, we performed a systematic evaluation of SLL-022CCP through

Identifiers

PMID42368158
PMCPMC13294904

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.